Artesunate Combined with Verteporfin Inhibits Uveal Melanoma by Regulation of the /yes-associated Protein Signaling Pathway

Overview

Journal Oncol Lett

Specialty Oncology

Date 2021 Jun 30

PMID 34188699

Citations 6

Authors

Xudong Jiu

Yang Liu

Jin Wen

Affiliations

Soon will be listed here.

Abstract

Uveal melanoma (UM) is the most common ocular malignancy and has no effective clinical treatment. Therefore, novel drugs to suppress UM tumor progression are urgently required. The present study aimed to clarify the underlying mechanism of the inhibitory effects of artesunate on UM. By using plasmid transfection and detecting apoptotic level, the present study identified artesunate as a potential candidate for UM treatment. Compared with those in the vehicle (DMSO)-treated control cells, artesunate enhanced the apoptotic rate and increased lactate dehydrogenase release, reactive oxygen species and IL1b and IL18 levels in C918 cells. Overexpression of yes-associated protein (YAP) or metastasis-associated lung adenocarcinoma transcript 1 () in C918 cells reversed the effects of artesunate and reduced the apoptotic rate compared with those observed in cells transfected with the negative control plasmid. Notably, verteporfin enhanced the effects of artesunate on C918 cells by increasing the apoptotic rate, indicating that combined therapy was more effective compared with treatment with artesunate alone. In conclusion, the results of the present study demonstrated that artesunate elevated the apoptotic rate and suppressed C918 cell viability by regulating the /YAP signaling pathway, and these effects were enhanced by supplementation with verteporfin. These results suggested that artesunate may exert an inhibitory effect on C918 cells and that the /YAP signaling may serve important role in mediating these effects, providing evidence of its potential for treating UM in the clinic.

Citing Articles

Anti-tumor mechanism of artesunate.

Fan X, Yan Y, Li Y, Song Y, Li B Front Pharmacol. 2024; 15:1483049.

PMID: 39525639 PMC: 11549674. DOI: 10.3389/fphar.2024.1483049.

TREM2, a critical activator of pyroptosis, mediates the anti‑tumor effects of piceatannol in uveal melanoma cells via caspase 3/GSDME pathway.

Jiu X, Li W, Liu Y, Liu L, Lu H Int J Mol Med. 2024; 54(5).

PMID: 39219277 PMC: 11410308. DOI: 10.3892/ijmm.2024.5420.

The Hippo signalling pathway and its impact on eye diseases.

Du Y J Cell Mol Med. 2024; 28(8):e18300.

PMID: 38613348 PMC: 11015399. DOI: 10.1111/jcmm.18300.

Lapatinib dysregulates HER2 signaling and impairs the viability of human uveal melanoma cells.

Shu W, Wang J, Zhu X, Wang K, Cherepanoff S, Conway R J Cancer. 2023; 14(18):3477-3495.

PMID: 38021158 PMC: 10647189. DOI: 10.7150/jca.88446.

Potential roles of lncRNA MALAT1-miRNA interactions in ocular diseases.

Nasrolahi A, Pour F, Salehi A, Kempisty B, Hajizadeh M, Feghhi M J Cell Commun Signal. 2023; 17(4):1203-1217.

PMID: 37870615 PMC: 10713964. DOI: 10.1007/s12079-023-00787-2.

References

Wang C, Guan Y, Lv M, Zhang R, Guo Z, Wei X . Manganese Increases the Sensitivity of the cGAS-STING Pathway for Double-Stranded DNA and Is Required for the Host Defense against DNA Viruses. Immunity. 2018; 48(4):675-687.e7. DOI: 10.1016/j.immuni.2018.03.017. View

Sun Y, Jiang T, Jia Y, Zou J, Wang X, Gu W . LncRNA MALAT1/miR-181a-5p affects the proliferation and adhesion of myeloma cells via regulation of Hippo-YAP signaling pathway. Cell Cycle. 2019; 18(19):2509-2523. PMC: 6738907. DOI: 10.1080/15384101.2019.1652034. View

Ogawa S, Fukuda A, Matsumoto Y, Hanyu Y, Sono M, Fukunaga Y . SETDB1 Inhibits p53-Mediated Apoptosis and Is Required for Formation of Pancreatic Ductal Adenocarcinomas in Mice. Gastroenterology. 2020; 159(2):682-696.e13. DOI: 10.1053/j.gastro.2020.04.047. View

Zanconato F, Cordenonsi M, Piccolo S . YAP/TAZ at the Roots of Cancer. Cancer Cell. 2016; 29(6):783-803. PMC: 6186419. DOI: 10.1016/j.ccell.2016.05.005. View

Huang J, Wu S, Barrera J, Matthews K, Pan D . The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell. 2005; 122(3):421-34. DOI: 10.1016/j.cell.2005.06.007. View

Mao X, Yu C, Li W, Li W . Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells. Cell Res. 2008; 18(8):879-88. DOI: 10.1038/cr.2008.86. View

McLaughlin C, Wu X, Jemal A, Martin H, Roche L, Chen V . Incidence of noncutaneous melanomas in the U.S. Cancer. 2005; 103(5):1000-7. DOI: 10.1002/cncr.20866. View

Li H, Li Q, Dang K, Ma S, Cotton J, Yang S . YAP/TAZ Activation Drives Uveal Melanoma Initiation and Progression. Cell Rep. 2019; 29(10):3200-3211.e4. PMC: 7871510. DOI: 10.1016/j.celrep.2019.03.021. View

Van Opdenbosch N, Lamkanfi M . Caspases in Cell Death, Inflammation, and Disease. Immunity. 2019; 50(6):1352-1364. PMC: 6611727. DOI: 10.1016/j.immuni.2019.05.020. View

10.

Wang Y, Gao W, Shi X, Ding J, Liu W, He H . Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. 2017; 547(7661):99-103. DOI: 10.1038/nature22393. View

11.

Zhang X, Hamblin M, Yin K . The long noncoding RNA Malat1: Its physiological and pathophysiological functions. RNA Biol. 2017; 14(12):1705-1714. PMC: 5731810. DOI: 10.1080/15476286.2017.1358347. View

12.

Brouwer N, Konstantinou E, Gragoudas E, Marinkovic M, Luyten G, Kim I . Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin. Invest Ophthalmol Vis Sci. 2021; 62(4):3. PMC: 8024781. DOI: 10.1167/iovs.62.4.3. View

13.

Uzun T, Toptas O, Saylan A, Carver H, Turkoglu S . Evaluation and Comparison of the Effects of Artesunate, Dexamethasone, and Tacrolimus on Sciatic Nerve Regeneration. J Oral Maxillofac Surg. 2019; 77(5):1092.e1-1092.e12. DOI: 10.1016/j.joms.2018.12.019. View

14.

Matsunaga S, Kishi T, Iwata N . Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2014; 18(5). PMC: 4376554. DOI: 10.1093/ijnp/pyu115. View

15.

Yao X, Zhao C, Yin H, Wang K, Gao J . Synergistic antitumor activity of sorafenib and artesunate in hepatocellular carcinoma cells. Acta Pharmacol Sin. 2020; 41(12):1609-1620. PMC: 7921114. DOI: 10.1038/s41401-020-0395-5. View

16.

. Selumetinib shows promise in metastatic uveal melanoma. Cancer Discov. 2013; 3(7):OF8. DOI: 10.1158/2159-8290.CD-NB2013-086. View

17.

Singh A, Bergman L, Seregard S . Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am. 2005; 18(1):75-84, viii. DOI: 10.1016/j.ohc.2004.07.002. View

18.

Wei H, Wang F, Wang Y, Li T, Xiu P, Zhong J . Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex. Cancer Sci. 2016; 108(3):478-487. PMC: 5378285. DOI: 10.1111/cas.13138. View

19.

Beccafico S, Morozzi G, Marchetti M, Riccardi C, Sidoni A, Donato R . Artesunate induces ROS- and p38 MAPK-mediated apoptosis and counteracts tumor growth in vivo in embryonal rhabdomyosarcoma cells. Carcinogenesis. 2015; 36(9):1071-83. DOI: 10.1093/carcin/bgv098. View

20.

Mijatovic S, Savic-Radojevic A, Pljesa-Ercegovac M, Simic T, Nicoletti F, Maksimovic-Ivanic D . The Double-Faced Role of Nitric Oxide and Reactive Oxygen Species in Solid Tumors. Antioxidants (Basel). 2020; 9(5). PMC: 7278755. DOI: 10.3390/antiox9050374. View